dc.contributor.author
Kühne, Britta A.
dc.contributor.author
Puig i Miquel, Teresa
dc.contributor.author
Ruiz-Martínez, Santiago
dc.contributor.author
Crous-Masó, Joan
dc.contributor.author
Planas, Marta
dc.contributor.author
Feliu, Lidia
dc.contributor.author
Cano Fernández, Amanda
dc.contributor.author
García, Maria Luisa
dc.contributor.author
Fritsche, Ellen
dc.contributor.author
Llobet Mallafré, Joan M. (Joan Maria)
dc.contributor.author
Gómez Catalán, Jesús
dc.contributor.author
Barenys Espadaler, Marta
dc.date.issued
2020-07-06T07:14:42Z
dc.date.issued
2020-07-06T07:14:42Z
dc.date.issued
2019-01-01
dc.date.issued
2020-07-06T07:14:42Z
dc.identifier
https://hdl.handle.net/2445/167697
dc.description.abstract
Epigallocatechin gallate (EGCG), the main catechin of green tea, is described to have potential health benefits in several fields like oncology, neurology or cardiology. Currently, it is also under pre-clinical investigation as a potential therapeutic or preventive treatment during pregnancy against developmental adverse effects induced by toxic substances. However, the safety of EGCG during pregnancy is unclear due to its proven adverse effects on neural progenitor cells' (NPCs) migration. As lately several strategies have arisen to generate new therapeutic agents derived from EGCG, we have used the rat 'Neurosphere Assay' to characterize and compare the effects of EGCG structurally related compounds and EGCG PEGylated PLGA nanoparticles on a neurodevelopmental key event: NPCs migration. Compounds structurally-related to EGCG induce the same pattern of NPCs migration alterations (decreased migration distance, decreased formation of migration corona, chaotic orientation of cellular processes and decreased migration of neurons at higher concentrations). The potency of the compounds does not depend on the number of galloyl groups, and small structure variations can imply large potency differences. Due to their lower toxicity observed in vitro in NPCs, 4,4′-bis[(3,4,5-trihydroxybenzoyl)oxy]-1,1′-biphenyl and EGCG PEGylated PLGA nanoparticles are suggested as potential future therapeutic or preventive alternatives to EGCG during prenatal period
dc.format
application/pdf
dc.publisher
Elsevier Ltd
dc.relation
Versió postprint del document publicat a: https://doi.org/10.1016/j.fct.2018.10.055
dc.relation
Food and Chemical Toxicology, 2019, vol. 123, p. 195-204
dc.relation
https://doi.org/10.1016/j.fct.2018.10.055
dc.rights
cc-by-nc-nd (c) Elsevier Ltd, 2019
dc.rights
http://creativecommons.org/licenses/by-nc-nd/3.0/es
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)
dc.subject
Suplements nutritius
dc.subject
Neurotoxicologia
dc.subject
Dietary supplements
dc.subject
Neurotoxicology
dc.title
Comparison of Migration Disturbance Potency of Epigallocatechin Gallate (EGCG) Synthetic Analogs and EGCG PEGylated PLGA Nanoparticles in Rat Neurospheres
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/acceptedVersion